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he Pursuit of
linically Relevant Measures
f Platelet Function After
ntiplatelet Drug Therapy*
ohn A. Cairns, MD, FRCPC, FACC,†
ohn Eikelboom, MBBS, MSC, FRACP‡
ancouver, British Columbia, and Hamilton,
ntario, Canada
lthough there is a marked reduction of cardiovascular
CV) events when clopidogrel is added to aspirin for
atients with a range of clinical presentations of vascular
isease and undergoing a variety of procedures, substantial
ates of CV events persist among treated patients (1,2). The
ccurrence of CV events in some treated patients and not in
thers often is explained by their demographics and by
emporal variation in the activity of their underlying vascular
iseases. However, an important potentially modifiable
ause of treatment failure is a poor response to clopidogrel
r clopidogrel resistance, defined as failure of the drug to
chieve the expected suppression of platelet function as
easured by various laboratory tests specific to its mecha-
ism of platelet inhibition (2,3).
See page 1968
If a test of platelet function could reliably identify patients
ith poor responsiveness to clopidogrel and therefore a
elatively higher rate of CV events, it would have great
otential clinical value. Among the many available tests of
latelet function, measures of platelet aggregation using
ight transmission aggregometry (LTA) and measures of
ntraplatelet signaling using the vasodilator-stimulated
hosphoprotein (VASP) phosphorylation assay have been
airly extensively studied. Both methods are predictive of
ubsequent cardiovascular events (4–8) and are reasonably
ell correlated (8–10). Although the VASP assay is specific
or inhibition by clopidogrel of the P2Y12 receptor pathway
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Medicine, University of British Columbia, Vancouver,P
ritish Columbia, Canada; and the ‡Department of Medicine, McMaster University,
amilton, Ontario, Canada.nd sample preparation is simpler than for LTA (9–11), it
s uncertain which test offers the best prediction of CV
vents (4).
Wallentin et al. (12) have previously reported a study in
hich they randomized 110 aspirin-treated patients with
table coronary artery disease to receive in a double-blind
ashion either prasugrel (60-mg load, 10-mg/day mainte-
ance) or clopidogrel (600-mg load, 75-mg/day mainte-
ance) for 28 days. They assessed platelet aggregation at
everal key time points in relation to load and maintenance
y LTA (reported as maximal platelet aggregation [MPA])
nd P2Y12 function by VASP assay (reported as platelet
eactivity index [PRI]). They also measured the active
etabolites of clopidogrel and prasugrel at these time
oints. They found that mean MPA and mean PRI were
oth significantly and substantially less with prasugrel than
ith clopidogrel at 2 h after the loading dose (LD).
uring maintenance dosing (MD) on days 14 and 28, the
PA and PRI values for prasugrel remained significantly
ess than those for clopidogrel. Mean area under the
ime-concentration curve (AUC) of the respective active
etabolite was higher with prasugrel than with clopi-
ogrel. The addition of the clopidogrel active metabolite
o the blood samples reduced the PRI in all patients
hose platelets were not already maximally inhibited.
he investigators concluded that the faster onset and
reater inhibition of P2Y12 receptor-mediated platelet
ggregation with prasugrel was accounted for by greater
nd more rapid generation of the active metabolite.
In this issue of the Journal, further analyses on the same
10 patients are reported (13). Patients were categorized as
ormal or poor responders to prasugrel and clopidogrel
sing 4 definitions that have been associated with worse
linical outcomes in studies of clopidogrel therapy (MPA
10%, MPA 50%, and residual platelet aggregation
RPA] 14% using LTA and PRI 50% using the VASP
ssay). After the LD, in the prasugrel group, the proportion
f patients with poor responsiveness varied from 0% to
6.4%, depending on the definition and the time after LD,
hereas in the clopidogrel group the proportion varied from
.6% to 92.5%. During the MD, the proportion of poor
esponders in the prasugrel group varied from 2% to 28%
nd in the clopidogrel group from 15% to 72%. The
roportion of patients with poor responsiveness was less in
he prasugrel than in the clopidogrel group for all tested
efinitions, both after LD and during MD.
The patients on clopidogrel who were classified as poor
esponders by each of the 4 definitions had significantly
ower concentrations of the active metabolite by AUC at 2 h
fter the LD and on the Day 29 MD. The numbers of poor
esponders were so low in the prasugrel group (except when
sing the RPA14% definition) that no formal comparison
f AUCs between the poor- and normal-responder groups
as made. Before clopidogrel administration (baseline), the
RI did not differ significantly between patients eventually
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esponders. At 2 h post-LD and Day 29 MD, the PRI had
ecreased to low values in the normal responders but was
elatively high in the poor responders. When the PRIs were
gain measured after the addition of the active clopidogrel
etabolite, they were found to be very low and similar in all
amples from both the poor- and normal-responder groups.
Although there was no prior hypothesis in regard to
atients with diabetes mellitus (DM), the investigators
bserved an excess of DM in the poor-responder groups and
arried out several exploratory analyses. There were 10
atients in the prasugrel group and 9 in the clopidogrel
roup who had previously been diagnosed with DM. The
raction of patients with DM was consistently higher in the
oor responsiveness groups at all time points and using all 4
efinitions. The concentrations of the active metabolite of
oth clopidogrel and prasugrel were nonsignificantly less at
oth 2 h post-LD and Day 29 MD in diabetic compared
ith nondiabetic patients. The addition of the clopidogrel
ctive metabolite to the samples resulted in low levels of
RI. The investigators concluded that the mechanism of
ncomplete platelet inhibition in the clopidogrel poor-
esponder groups and in diabetic patients is lower levels of
he active metabolite and not differences in P2Y12 receptor
unction.
New in this report is the approach of dichotomizing the
atients as poor responders or normal responders based on
heir platelet responsiveness in relation to cutoff values for 3
ifferent expressions of platelet responsiveness using LTA,
nd 1 using the VASP assay, each of which has previously
een reported to correlate with subsequent cardiovascular
vents. They show that the proportion of nonresponsive
atients varies with the different tests, but is consistently less
ith prasugrel than with clopidogrel. They also show that
he levels of active metabolite are lower in the patients
ategorized as poor responders, and that almost complete
latelet suppression can be achieved by the addition of the
etabolite to the samples.
This exercise moves us closer to the possibility of a
aboratory test that might predict poor clinical responses and
rompt changes in therapy in those patients found to be
oor responders. However, LTA and the VASP assay are
urrently research tests with inherent challenges of quality
ontrol, high cost, and long turnaround times. Furthermore,
lthough the mean levels of platelet responsiveness in the
oor responders group are higher than in the normal
ubjects, there is extensive overlap, so that appropriate
linical interventions would be unclear unless the groups
ould be more sharply distinguished, as is possible, for
nstance, with use of the international normalized ratio in
onitoring warfarin therapy. The proportion of patients
dentified as poor responders was highest when defined as
PA 14% and progressively lower when defined as PRI
50%, MPA50%, and MPA10%. It is likely that the
ensitivity for prediction of a patient with a future cardio-
ascular event is highest in the first group, but that theositive predictive rate will be low, as was determined by
rere et al. (4). Calculation of the receiver-operator char-
cteristic curves of each test would be necessary to establish
linically useful cutoff values (4,14). If these issues can be
uccessfully addressed, clinical trials of various management
trategies incorporating assessments of platelet inhibition
ill be required to sort out the options for patients found to
ave clopidogrel resistance (e.g., GRAVITAS [Gauging
esponsiveness With a VerifyNow Assay—Impact on
hrombosis and Safety] [15]). Complex, expensive, and
ime-consuming assessments of platelet reactivity or of
evels of the clopidogrel active metabolite may be obviated
y newer therapies with less response variability than clo-
idogrel. Prasugrel seems to have a much more favorable
harmacokinetic profile than clopidogrel, with fewer non-
esponsive patients (12,16), and new agents such as
ZD6140 and cangrelor directly target the P2Y12 receptor
nd are reversible (17). However, the challenges to optimiz-
ng the benefits (fewer CV events) and risks (more bleeding)
f more potent platelet inhibition should not be minimized.
It is already known that diabetic patients have higher
ates of vascular events and are less responsive to aspirin and
lopidogrel than nondiabetic patients (18). Erlinge et al.
13) suggest that the poor responsiveness to clopidogrel may
t least in part be the result of relatively less generation of
he active metabolite in diabetic than in nondiabetic patients,
erhaps as a result of increased esterase activity, reduced
astric motility, or alterations at the megakaryocyte level.
owever, their observations in diabetic patients must be
egarded with caution because there was no prior hypothesis
hat there would be an excess of poor responders among
iabetic patients or that they would have lower levels of the
ctive metabolite. The numbers of diabetic patients were
mall, and these preliminary findings require confirmation.
The study by Erlinge et al. (13) contributes useful
nsights into the mechanisms and laboratory diagnosis of
lopidogrel resistance, but many important issues remain
nresolved. The complexity of the issues reinforces the
ecommendation in current guidelines that platelet function
ssessments be confined to research studies (1,19), while
ighlighting the promise of new antiplatelet therapies that
ay circumvent some of the therapeutic limitations of
lopidogrel.
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ealth Care Centre, Room 9113, 2775 Laurel Street, Vancouver,
ritish Columbia V5Z 1M9, Canada. E-mail: jacairns@medd.
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